Logo

Promega to Distribute Gene Expression Assays Based on EraGen Technology

Mar 09, 2004

NEW YORK, March 9 (GenomeWeb News) - Promega and EraGen Biosciences have entered a distribution partnership that gives Promega exclusive rights to quantitative gene expression assays using technology developed by EraGen.

Promega has global distribution rights for the assays. Promega will develop and manufacture reagent systems in its Madison, Wis., facility, while EraGen will provide its patented chemistry and proprietary software for nucleic acid detection.

The launch of the assays, which will be marketed under the Promega brand, is scheduled for this year.

Breaking News
The Scan

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.

Survey Sees Genetic Literacy on the Rise, Though Further Education Needed

Survey participants appear to have higher genetic familiarity, knowledge, and skills compared to 2013, though 'room for improvement' remains, an AJHG paper finds.

Study Reveals Molecular, Clinical Features in Colorectal Cancer Cases Involving Multiple Primary Tumors

Researchers compare mismatch repair, microsatellite instability, and tumor mutation burden patterns in synchronous multiple- or single primary colorectal cancers.

FarGen Phase One Sequences Exomes of Nearly 500 From Faroe Islands

The analysis in the European Journal of Human Genetics finds few rare variants and limited geographic structure among Faroese individuals.